黑色素瘤中MITF高表达与超级增强子相关并被CDK7抑制所抑制
该研究探讨黑色素瘤中MITF过表达的调控机制,发现超级增强子是一些黑色素瘤细胞系和肿瘤中MITF过表达的重要决定因素,而共价CDK7抑制剂THZ1可在体外和体内抑制黑色素瘤细胞生长,并在部分细胞系中破坏MITF和SOX10的超级增强子装置,从而降低其细胞内水平。结果揭示了MITF调控的新维度,并提示CDK7抑制可能成为剥夺致癌转录、抑制黑色素瘤肿瘤生长的潜在策略。
要点
- 超级增强子是一些黑色素瘤细胞系和肿瘤中MITF过表达的重要决定因素。
- 黑色素瘤细胞在体外和体内对CDK7抑制高度敏感,THZ1可破坏部分细胞系中MITF和SOX10的超级增强子装置。
- CDK7抑制是剥夺致癌转录、抑制黑色素瘤肿瘤生长的潜在策略。
核心结论
- 超级增强子是一些黑色素瘤细胞系和肿瘤中MITF过表达的重要决定因素,CDK7抑制是剥夺致癌转录、抑制黑色素瘤肿瘤生长的潜在策略。
研究设计与样本
- 研究使用黑色素瘤细胞系和肿瘤,在体外和体内评估CDK7抑制对黑色素瘤细胞生长的影响。
主要发现
- MITF过表达偶尔可由基因扩增解释,但超级增强子也是一些黑色素瘤细胞系和肿瘤中MITF过表达的重要决定因素。
- 黑色素瘤细胞在体外和体内对CDK7抑制高度敏感。
- THZ1可在部分细胞系中破坏MITF和SOX10的超级增强子装置,从而降低其细胞内水平。
临床怎么用
- 作者认为CDK7抑制是剥夺致癌转录和抑制黑色素瘤肿瘤生长的潜在策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cutaneous melanoma is an aggressive tumor that accounts for most skin cancer deaths. Among the physiological barriers against therapeutic success is a strong survival program driven by genes such as MITF that specify melanocyte identity, a phenomenon known in melanoma biology as lineage dependency. MITF overexpression is occasionally explained by gene amplification, but here we show that super-enhancers are also important determinants of MITF overexpression in some melanoma cell lines and tumors. Although compounds that directly inhibit MITF are unavailable, a covalent CDK7 inhibitor, THZ1, has recently been shown to potently suppress the growth of various cancers through the depletion of master transcription-regulating oncogenes and the disruption of their attendant super-enhancers. We also show that melanoma cells are highly sensitive to CDK7 inhibition both in vitro and in vivo and that THZ1 can dismantle the super-enhancer apparatus at MITF and SOX10 in some cell lines, thereby extinguishing their intracellular levels. Our results show a dimension to MITF regulation in melanoma cells and point to CDK7 inhibition as a potential strategy to deprive oncogenic transcription and suppress tumor growth in melanoma.
引用
- Eliades P, Abraham BJ, Ji Z, et al. High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma. J Invest Dermatol. 2018. PMID: 29408204. doi:10.1016/j.jid.2017.09.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。